Literature DB >> 28368465

Intratumoral heterogeneity in gastric cancer: a new challenge to face.

M Alsina1, I Gullo2,3,4,5, F Carneiro2,3,4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28368465     DOI： 10.1093/annonc/mdx134

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  9 in total

1.  Human epidermal growth factor receptor 2 overexpression in gastric and gastroesophageal junction adenocarcinoma in patients seen at the University Teaching Hospital, Lusaka, Zambia.

Authors:  Chimwasu Kasochi; Peter Julius; Isaac Mweemba; Violet Kayamba
Journal:  Afr Health Sci       Date:  2020-12       Impact factor: 1.108

2.  Impact of AADAC gene expression on prognosis in patients with Borrmann type III advanced gastric cancer.

Authors:  Yufei Wang; Tianyi Fang; Yimin Wang; Xin Yin; Lei Zhang; Xinghai Zhang; Daoxu Zhang; Yao Zhang; Xibo Wang; Hao Wang; Yingwei Xue
Journal:  BMC Cancer       Date:  2022-06-09       Impact factor: 4.638

3.  Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer.

Authors:  Whitney P Kirschbrown; Bei Wang; Ihsan Nijem; Atsushi Ohtsu; Paulo M Hoff; Manish A Shah; Lin Shen; Yoon-Koo Kang; Maria Alsina; Sandhya Girish; Amit Garg
Journal:  Cancer Chemother Pharmacol       Date:  2019-06-10       Impact factor: 3.333

4.  VGLL3 is a prognostic biomarker and correlated with clinical pathologic features and immune infiltrates in stomach adenocarcinoma.

Authors:  Lihua Zhang; Longhai Li; Yong Mao; Dong Hua
Journal:  Sci Rep       Date:  2020-01-28       Impact factor: 4.379

5.  Histological diversity and molecular characteristics in gastric cancer: relation of cancer stem cell-related molecules and receptor tyrosine kinase molecules to mixed histological type and more histological patterns.

Authors:  Kazuhiro Sentani; Takeharu Imai; Go Kobayashi; Tetsutaro Hayashi; Naomi Sasaki; Naohide Oue; Wataru Yasui
Journal:  Gastric Cancer       Date:  2020-10-28       Impact factor: 7.370

Review 6.  Tumor heterogeneity of gastric cancer: From the perspective of tumor-initiating cell.

Authors:  Jian-Peng Gao; Wei Xu; Wen-Tao Liu; Min Yan; Zheng-Gang Zhu
Journal:  World J Gastroenterol       Date:  2018-06-28       Impact factor: 5.742

7.  Sp1-Induced FNBP1 Drives Rigorous 3D Cell Motility in EMT-Type Gastric Cancer Cells.

Authors:  Bo Kyung Yoon; Nahee Hwang; Kyu-Hye Chun; Yoseob Lee; Tatiana Patricia Mendes Duarte; Jae-Won Kim; Tae-Hyun Kim; Jae-Ho Cheong; Sungsoon Fang; Jae-Woo Kim
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923

8.  Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials.

Authors:  Hong Xiang; Lucy Liu; Yuying Gao; Ago Ahene; Helen Collins
Journal:  Cancer Chemother Pharmacol       Date:  2021-08-12       Impact factor: 3.333

Review 9.  Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond.

Authors:  Maria Alsina; Josep Tabernero; Marc Diez
Journal:  Cancers (Basel)       Date:  2022-03-10       Impact factor: 6.639
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.